VIDAS® TB-IGRA assay for diagnosing tuberculosis infection in people living with HIV: A preliminary study

IF 4.8 2区医学 Q1 INFECTIOUS DISEASES

International Journal of Infectious Diseases Pub Date : 2025-06-15 DOI:10.1016/j.ijid.2025.107955

Aliasgar Esmail , Jeremi Swanepoel , Suzette Oelofse , Brandon Reyneke , Anil Pooran , Shameem Jaumdally , Lara Wiese , Keertan Dheda

{"title":"VIDAS® TB-IGRA assay for diagnosing tuberculosis infection in people living with HIV: A preliminary study","authors":"Aliasgar Esmail , Jeremi Swanepoel , Suzette Oelofse , Brandon Reyneke , Anil Pooran , Shameem Jaumdally , Lara Wiese , Keertan Dheda","doi":"10.1016/j.ijid.2025.107955","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>The diagnosis of presumed latent tuberculosis (TB) infection (LTBI) is problematic in people living with HIV (PLWH) because of sub-optimal sensitivity and high indeterminate rates, especially in those with advanced immunosuppression. Better diagnostic tools for LTBI are needed in this sub-population.</div></div><div><h3>Methods</h3><div>We compared the sensitivity of VIDAS TB-IGRA, a fully automated RD1-specific new interferon-ϒ-release assay (IGRA), to QFT-Plus in 77 PLWH with active pulmonary TB who had varying CD4 counts. Sputum culture positivity served as the reference standard for active TB.</div></div><div><h3>Results</h3><div>The sensitivity of VIDAS TB-IGRA was similar to QFT-Plus overall [90.9% (70/77) vs 92.0% (69/75)], in those with CD4 <200 cells/mm<sup>3</sup>, [88.9% (40/45) vs 88.6% (39/44)], and in those with CD4 <100 [85.7% (18/21) vs 80.0% (16/20)]. However, VIDAS TB-IGRA had a higher sensitivity in those with CD4 <50 [92.3% (12/13) vs 75% (9/12)] and fewer indeterminate results overall [0 vs 2]. When the indeterminate results in this subgroup were regarded as negative, the comparative sensitivity was [92.3% (12/13) vs 69.2% (9/13)].</div></div><div><h3>Conclusion</h3><div>VIDAS TB-IGRA had a similar sensitivity to QFT-Plus in PLWH. Whether VIDAS TB-IGRA sensitivity is significantly better at lower CD4 counts remains to be confirmed in a larger study. These data have implications for the diagnosis of LTBI in those with advanced immunosuppression.</div></div>","PeriodicalId":14006,"journal":{"name":"International Journal of Infectious Diseases","volume":"158 ","pages":"Article 107955"},"PeriodicalIF":4.8000,"publicationDate":"2025-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Infectious Diseases","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1201971225001791","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

Abstract

Background

The diagnosis of presumed latent tuberculosis (TB) infection (LTBI) is problematic in people living with HIV (PLWH) because of sub-optimal sensitivity and high indeterminate rates, especially in those with advanced immunosuppression. Better diagnostic tools for LTBI are needed in this sub-population.

Methods

We compared the sensitivity of VIDAS TB-IGRA, a fully automated RD1-specific new interferon-ϒ-release assay (IGRA), to QFT-Plus in 77 PLWH with active pulmonary TB who had varying CD4 counts. Sputum culture positivity served as the reference standard for active TB.

Results

The sensitivity of VIDAS TB-IGRA was similar to QFT-Plus overall [90.9% (70/77) vs 92.0% (69/75)], in those with CD4 <200 cells/mm³, [88.9% (40/45) vs 88.6% (39/44)], and in those with CD4 <100 [85.7% (18/21) vs 80.0% (16/20)]. However, VIDAS TB-IGRA had a higher sensitivity in those with CD4 <50 [92.3% (12/13) vs 75% (9/12)] and fewer indeterminate results overall [0 vs 2]. When the indeterminate results in this subgroup were regarded as negative, the comparative sensitivity was [92.3% (12/13) vs 69.2% (9/13)].

Conclusion

VIDAS TB-IGRA had a similar sensitivity to QFT-Plus in PLWH. Whether VIDAS TB-IGRA sensitivity is significantly better at lower CD4 counts remains to be confirmed in a larger study. These data have implications for the diagnosis of LTBI in those with advanced immunosuppression.

查看原文本刊更多论文

用于诊断HIV感染者结核感染的VIDAS®TB-IGRA检测：初步研究

背景：在HIV感染者（PLWH）中，诊断推定潜伏性结核感染（LTBI）是一个问题，因为其灵敏度不佳，且不确定率高，特别是在晚期免疫抑制患者中。这一亚群需要更好的LTBI诊断工具。方法：我们比较了VIDAS®TB-IGRA（一种全自动rd1特异性新干扰素-ϒ-release检测（IGRA））对77例CD4计数不同的活动性肺结核患者QFT®-Plus的敏感性。痰培养阳性作为活动性结核的参考标准。结果：VIDAS®TB-IGRA的敏感性与QFT®-Plus总体相似[90.9%（70/77）对92.0%(69/75)]，在CD4 3组中，[88.9%（40/45）对88.6%(39/44)]，在CD4组中，结论：VIDAS®TB-IGRA与QFT®-Plus在PLWH中具有相似的敏感性。是否VIDAS®TB-IGRA敏感性在较低CD4计数下显着更好，仍有待于更大规模的研究证实。这些数据对晚期免疫抑制患者LTBI的诊断具有指导意义。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Journal of Infectious Diseases 医学-传染病学

CiteScore

18.90

自引率

2.40%

发文量

1020

审稿时长

30 days

期刊介绍： International Journal of Infectious Diseases (IJID) Publisher: International Society for Infectious Diseases Publication Frequency: Monthly Type: Peer-reviewed, Open Access Scope: Publishes original clinical and laboratory-based research. Reports clinical trials, reviews, and some case reports. Focuses on epidemiology, clinical diagnosis, treatment, and control of infectious diseases. Emphasizes diseases common in under-resourced countries.